Skip to main
IMNN
IMNN logo

Imunon Inc (IMNN) Stock Forecast & Price Target

Imunon Inc (IMNN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Imunon Inc exhibits a positive outlook based on the strong clinical performance of its lead product, IMNN-001, which has shown promising outcomes in Phase II trials for advanced ovarian cancer, including enhanced overall survival metrics and improved hazard ratios. The upcoming pivotal Phase 3 trial, supported by favorable FDA interactions regarding trial design, adds to the confidence in the therapeutic's potential as a transformative addition to current treatment protocols. Moreover, continued validation of the TheraPlas platform’s DNA-mediated immunotherapy approach, alongside demonstrated safety and efficacy, reinforces the likelihood of successful outcomes in future clinical development.

Bears say

Imunon Inc. reports a 9% year-over-year decline in operating expenses, which indicates some level of cost management; however, this may not be sufficient to offset concerns related to its revenue generation potential. The company's approach to staggered approval timelines, particularly anticipated European approvals occurring three years post-U.S. approvals, suggests a prolonged path to market that could inhibit revenue growth. Furthermore, despite the innovative nature of its treatments, the reliance on advancing through clinical stages without immediate commercial outcomes positions the company at financial risk in the competitive biotechnology landscape.

Imunon Inc (IMNN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Imunon Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Imunon Inc (IMNN) Forecast

Analysts have given Imunon Inc (IMNN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Imunon Inc (IMNN) has a Strong Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Imunon Inc (IMNN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.